Abstract. Acetaminophen-induced hepatotoxicity results from hepatic enzymatic oxidation of acetaminophen to a toxic, electrophilic intermediate. Acetaminophen is ordinarily eliminated after conjugation with glucuronic acid and sulfate to nontoxic derivatives. Cimetidine has been shown to inhibit the hepatic oxidation of a number of drugs and to protect rats from acetaminophen-induced hepatic necrosis. The aim of this study was to define the mechanism by which cimetidine reduced acetaminophen-induced hepatic necrosis and to determine whether inhibition of formation of the reactive metabolite(s) of acetaminophen occurred also in man. In vivo cimetidine pretreatment decreased covalent binding of [3H]acetaminophen to the liver from 552±23.8 to 170±31.6 nmol/g protein 2 h after a toxic dose of acetaminophen in 3-methylcholanthrene pretreated rats (P < 0.05). Cimetidine pretreatment also significantly reduced the rate of hepatic glutathione depletion. Both cimetidine and metiamide produced dose-dependent inhibition of acetaminophen oxidation in vitro, whereas inhibition by ranitidine and cimetidine sulfoxide was quantitatively less. Inhibition ofacetaminophen oxidation by cimetidine and metiamide was primarily competitive MM, respectively. By contrast, cimetidine inhibited acetaminophen glucuronidation minimally with a Ki of 1.39±0.23 mM. Similar results were obtained using human liver microsomes as a source of enzymes. In a doserelated fashion, cimetidine also reduced acetaminopheninduced toxicity to human lymphocytes when incubated with microsomes and NADPH. Pharmacokinetics of acetaminophen elimination were studied in normal volunteers with and without co-administration ofcimetidine 300 mg every 6 h. In normal volunteers, cimetidine decreased the fractional clearance ofthe oxidized (potentially toxic) metabolites of acetaminophen more than the conjugated metabolites. This finding confirmed the hypothesis that cimetidine is a relatively selective inhibitor of the oxidation of acetaminophen to reactive metabolites in man as well as in animals. When considered together with the results of previous studies showing improved survival and decreased hepatotoxicity in acetaminophenpoisoned animals, the present results provide a rational basis for assessing possible benefits ofcimetidine treatment of acetaminophen overdoses in man.
Introduction pathways account for -80-90% of the metabolism of acetaminophen, except after large doses, when sulfation may become saturated (4) . The oxidized metabolites of acetaminophen are excreted in urine as mercapturic acid and cysteine conjugates, which represent degradation products of the acetaminophenglutathione adduct. At low doses of acetaminophen these compounds serve as an index of the potentially toxic oxidation of acetaminophen while the glucuronide and sulfate conjugates represent nontoxic elimination. Current therapy of acetaminophen overdoses includes administration of N-acetylcysteine, which protects against necrosis by increasing synthesis of glutathione, providing active sulfate, and/or by reduction of the electrophilic intermediate (N-acetyl-p-benzoquinoneimine) back to the parent compound (5) .
Cimetidine, a 4-5 substituted imidazole used widely as a histamine H2-receptor antagonist, has been demonstrated to cause dose-related inhibition of cytochrome P-450-mediated oxidation both in vivo and in vitro (6) (7) (8) . This inhibition of cytochrome P-450-mediated drug metabolism by cimetidine seems to be related to its imidazole structure rather than to its H2-receptor antagonist potency. Ranitidine, a substituted furan, exhibits higher H2-receptor antagonist potency, but is far less active than cimetidine in inhibiting drug oxidation (6) (7) (8) . Fur- thermore, this inhibition of oxidative drug metabolism appears to be relatively selective, as glucuronidation of drugs has been reported to be unaffected by cimetidine both in vivo and in vitro (7, 9) . Thus, cimetidine (and related imidazole derivatives) should theoretically prevent the toxic oxidation of acetaminophen while allowing nontoxic conjugation to continue unaffected. Several studies have recently demonstrated cimetidine to be as effective as N-acetylcysteine in preventing acetaminophen-induced hepatic necrosis and death in rats (10) (11) (12) . The aims of the present studies were to extend these observations, to define the mechanism by which cimetidine prevents acetaminophen hepatotoxicity and to determine whether cimetidine might protect against hepatic necrosis in man.
Methods
Animals. Male Fischer 344 rats (Harlan Sprague-Dawley Inc., Indianapolis, IN) weighing 100-175 g were pretreated with a single intraperitoneal dose of 3-methylcholanthrene (3-MC)' ( Total hepatic glutathione levels in the initial supernatant after homogenization of the liver were measured using the method of Tietze (14) . Metabolism of acetaminophen by human microsomes. Liver was obtained from a cadaveric renal transplant donor who died as a result of intracranial bleeding. The liver was removed at surgery and perfused with 4.0 liter of ice-cold saline and frozen at -70'C for 2 wk before preparation of microsomes as described above (15) . Oxidation of acetaminophen and formation of acetaminophen glucuronide were determined as described above.
Acetaminophen-induced human lymphocyte toxicity. Lymphocytes were separated from heparinized venous blood collected from normal volunteers by centrifugation through Ficoll-Paque (Pharmacia Fine Chemicals Piscataway, NJ) (17) . Hepatic microsomes were prepared from the livers of Fischer 344 rats, which had been pretreated with an intraperitoneal dose of 20 mg/kg of 3-MC 72 h before killing. Lymphocytes (I X 106) were incubated for 3 h with 20 mM acetaminophen, an NADPH-generating system (17) , and varying concentrations of cimetidine (0.1-1.7 mM) in the presence of 2 mg/ml of microsomes and 02 according to the method of Spielberg (17 Effects ofcimetidine on the metabolism ofacetaminophen in normal volunteers. The distribution and elimination of acetaminophen were studied in normal human volunteers. All subjects gave written informed consent and the protocol was approved by the institutional review committee for clinical investigation. After an overnight fast, each subject was given 1.5 g of acetaminophen in capsules (Tylenol, extrastrength) with 100 ml of water. Venous blood was collected from an indwelling heparin lock and plasma separated and frozen at -20'C until determination of plasma acetaminophen concentration. Samples were collected at 0, 0.5, 0.75, 1.0, 2, 3, 4, 6, and 8 h after oral acetaminophen administration. Urine was collected from each subject for 24 h, beginning at the time of acetaminophen dosing. Plasma acetaminophen concentrations and urinary acetaminophen metabolite concentrations were determined as previously described (18) . The oral clearance (Cl)) of acetaminophen from plasma was determined by calculation of the area under the curve after linear regression of the logarithm of plasma concentration vs. time as follows: Cl0 = Dose/AUC0, assuming absorption to be rapid and complete. Plasma half-life for the elimination phase (t'/2) and volume of distribution for the elimination phase were determined as previously described (18 imals receiving acetaminophen only, covalent binding of acetaminophen increased linearly with time reaching a maximum of 552±23.8 nmol acetaminophen bound/g liver protein at 90 min after injection of acetaminophen. By contrast, in animals pretreated with cimetidine the covalent binding of acetaminophen was significantly lower at all time points (P < 0.05) and reached a maximum of 170±31.6 nmol acetaminophen bound/g liver protein at 120 min (Fig. 1 A) .
Hepatic glutathione depletion by acetaminophen. Hepatic glutathione was rapidly depleted in animals receiving acetaminophen only, reaching a minimum of 13.9±1.28% of initial levels at 60 min after injection of acetaminophen. Total glutathione stores also decreased with time after administration of acetaminophen in rats pretreated with cimetidine, but at a slower rate reaching a minimum of 30.3±1.91% of initial values at 120 min after injection of acetaminophen (Fig. 1 B) . Total hepatic glutathione concentration in cimetidine-pretreated rats was significantly greater than those in control animals up to (Fig. 2) . A dose-dependent inhibition of the formation of the acetaminophen-cysteine adduct was observed for both cimetidine and metiamide at a substrate concentration of 1.0 mM acetaminophen. For these two H2-receptor antagonists only 44% of control activity was present at inhibitor concentrations of 1.0 mM. Ranitidine and cimetidine sulfoxide were far less potent in inhibiting the formation of acetaminophen-cysteine adduct. At similar inhibitor concentrations (1.0 mM) activity was 78% of control for ranitidine and 80% for cimetidine sulfoxide. At higher substrate concentrations (10 mM acetaminophen), similar inhibition was observed for 1.0 mM cimetidine, 50% of control activity, and for 1.0 mM metiamide, 54% of control activity. However, essentially no inhibition occurred with 1.0 mM ranitidine or 1.0 mM cimetidine sulfoxide (Fig. 3) . Inhibition of the cysteine adduct formation by cimetidine was mixed, but primarily competitive, when plotted using Lineweaver-Burk plots of 1/v vs. 1/s (Fig. 4) Acetaminophen glucuronidation. The effect ofcimetidine on glucuronidation of acetaminophen in rat microsomes was significantly less than on acetaminophen oxidation. At higher concentrations of cimetidine, minimal competitive inhibition of the formation ofacetaminophen glucuronide was observed (Fig.  5) . The inhibition constant K,, for cimetidine in inhibiting glucuronidation was 1.39±0.23 mM, which is significantly higher than the inhibition of oxidation ofacetaminophen by cimetidine (P < 0.0001). Incubation of acetaminophen with 5.0 mM UDPGA and human microsomes resulted in enzymatic formation of acetaminophen glucuronide with Km = 5.50 mM and Vma, = 0.51 nmol/mg protein per h. Cimetidine again competitively inhibited this reaction, with an inhibition constant of 7.90 mM (Table 1) .
Cimetidine-related inhibition ofacetaminophen-induced human lymphocyte toxicity. Incubation of20.0 mM acetaminophen with human lymphocytes in the presence of microsomes and an NADPH-generating system resulted in a 36.9±9.5% killing of lymphocytes at 24 h as indicated by trypan blue dye exclusion (n = 5). At a concentration of 1.7 mM cimetidine only 18 .9±5.8% of cells were dead at 24 h, a 49% decrease in toxicity (P < 0.05). Using lymphocytes from two subjects, increasing concentrations of cimetidine produced dose-dependent decreases in acetaminophen-related toxicity (Fig. 6) . Lactate dehydrogenase released into the culture medium (data not shown) agreed with the data obtained using trypan blue dye exclusion.
Effects ofcimetidine upon pharmacokinetics ofacetaminophen in normal volunteers. The effects ofcimetidine upon pharmacokinetic parameters of acetaminophen are summarized in Table II . As shown there was a 24% reduction in mean plasma clearance of acetaminophen (P < 0.05), however, no change was observed in the plasma elimination rate or half-life. Urinary recovery of acetaminophen and its metabolites were not significantly different in subjects while taking cimetidine compared with the base-line period. Recoveries ranged from 65 to 105%. Urinary recovery ofthe oxidized metabolites was decreased from 9.26±2.08 to 6.38±0.74% but these results did not reach statistical significance. However, the fractional clearance of the oxidized metabolites is a more accurate index of in vivo conversion of acetaminophen to its oxidized metabolites, since clearance = VmaJ/Km. Cimetidine significantly decreased the fractional clearance of acetaminophen by oxidation to 53% of the control period. Cimetidine also significantly decreased the fractional clearance of acetaminophen by glucuronidation to 76% of the control period. The fractional clearance of acetaminophen sulfate was not significantly changed by cimetidine treatment. These results are summarized in Table III . These data suggest that in man cimetidine inhibits oxidation of acetaminophen and to a lesser extent glucuronidation of acetaminophen.
Discussion
The results described in this study demonstrate that cimetidine inhibits the potentially toxic oxidation of acetaminophen in vitro. By contrast, one of the major routes of elimination of * P < 0.0001, oxidation vs. glucuronidation. § Acetaminophen glucuronidation was followed in the above-mentioned microsomal preparations incubated in the presence or absence of cimetidine by measuring acetaminophen glucuronide. glucuronidation. Thus, cimetidine is a relatively selective inhibitor of the potentially toxic oxidation of acetaminophen, especially at lower concentrations of this drug that are likely to be achieved in the liver in vivo (6) . The relative lack of inhibition of acetaminophen oxidation seen in vitro in the rat with cimetidine sulfoxide suggests that the parent compound rather than its oxidized metabolite is responsible for the dose-dependent inhibition of cytochrome P-450-mediated oxidation of acetaminophen. Furthermore, in other studies in the rat, metiamide, another imidazole derivative H2-receptor antagonist, also inhibited acetaminophen oxidation, whereas ranitidine, a furan derivative H2-antagonist had a much smaller effect (Figs. 2 and Cimetidine-related inhibition of the oxidation of acetaminophen to its reactive metabolite is an important toxicological effect. Both pretreatment and posttreatment with cimetidine have been reported to increase survival of animals given lethal doses of acetaminophen (10) (11) (12) . Cimetidine also appears to inhibit the formation of the reactive metabolite of acetaminophen in vivo. The rate and absolute degree of acetaminopheninduced glutathione depletion were lower in rats pretreated with cimetidine than in those receiving saline. Furthermore, the amount of acetaminophen covalently bound to liver proteins, an index of the potential toxicity of acetaminophen, was lower in cimetidine-pretreated rats (Fig. 1) . In the rat cimetidine has a relatively short half-life, which is -45 min (21) . By 120 min after receiving acetaminophen the amount of cimetidine remaining in the plasma would be <20% of the initial levels. This short half-life could explain the continuing decrease in hepatic glutathione depletion observed in our study. Cimetidine also protected human lymphocytes from acetaminophen-related toxicity. This protection was dependent on the dose of cimetidine. Since cimetidine was removed from the lymphocytes at the same time as acetaminophen, NADPH and microsomes were removed, this finding is consistent with the hypothesis that cimetidine inhibits the formation of toxic acetaminophen metabolites.
The results ofthe present study demonstrate that cimetidine significantly reduces the clearance ofacetaminophen by oxidative (potentially toxic) pathways in human volunteers. Previous studies have shown that the elimination of acetaminophen metabolites in urine parallels the elimination of the parent compound from plasma (22) . The fractional clearance of each metabolite thus represents the contribution of each separate enzymatic pathway to the overall metabolism of acetaminophen. The actual effects of cimetidine on the formation of the toxic intermediate ofacetaminophen are not easily measured in man. After the drug is oxidized, further conjugation with glutathione occurs and ultimately this glutathione adduct is degraded to mercapturic acid and cysteine derivates before final urinary elimination. These additional metabolic steps may compound interpretation of changes in fractional clearance of acetaminophen by oxidation. Glucuronidation of acetaminophen is significantly reduced by cimetidine, but to a lesser extent than oxidation. Although cimetidine does not affect glucuronidation of the benzodiazepines, lorazepam, and oxazepam, in man, the observed inhibition is consistent with the in vitro data on glucuronidation of acetaminophen in rat and human microsomes in the present study. These findings are in contrast to those of Abernethy et al. (12) , who reported that clearance of acetaminophen was unchanged after cimetidine. In that study acetaminophen was given intravenously rather than orally as in the present study. Although complete absorption ofacetaminophen is assured by intravenous administration of acetaminophen, changes in hepatic blood flow rather than changes in enzyme activity may play a larger role in determining clearance, since the extraction ratio of acetaminophen is intermediate rather than low. Our results do however support the hypothesis that cimetidine is a more potent inhibitor of the potentially toxic oxidation of acetaminophen than of the nontoxic conjugation.
Previous studies have demonstrated that sulfhydryl compounds such as cysteamine, cysteine, N-acetylcysteine, a-mercaptoproprionylglycine, propylthiouracil, and others can prevent acetaminophen-induced hepatic necrosis (23) (24) (25) (26) (27) (28) (29) . Although some of these compounds may inhibit the formation of the toxic metabolite of acetaminophen, their primary mechanism ofaction appears to be related to their ability to prevent covalent binding and/or toxicity of the reactive intermediate after its formation. These agents may form covalent adducts with reactive acetaminophen metabolites directly or in reactions mediated by glutathione-S-transferase or they may detoxify the metabolite by serving as reducing agents or through other membrane stabilizing effects. Consistent with this hypothesis, we found metiamide, which has a thiol sulfur, to be more effective in preventing in vitro covalent binding than cimetidine, although other studies of oxidative metabolism showed metiamide to be equal to or less potent than cimetidine as an inhibitor. Piperonyl butoxide and metyrapone also prevent acetaminophen-induced damage in animal models (1, 30) . These agents are well recognized inhibitors of cytochrome P-450-mediated oxidation, the metabolic pathway through which acetaminophen is converted to a toxic, electrophilic intermediate. However, piperonyl butoxide is toxic and both agents have potentially undesirable side effects (1, 30) . Therapy with N-acetylcysteine is frequently complicated by nausea and vomiting when this agent is given orally (31) . Cimetidine is a remarkably safe drug when used in usual therapeutic doses such as those given in this study and may be given intravenously. Inhibition of drug oxidation is rapid in onset and is reversible after the drug is eliminated by renal clearance (32) . Evaluation of the potential benefit of cimetidine or any other agent for acetaminophen hepatotoxicity in man is difficult. Our results do not prove that cimetidine is effective for reducing acetaminophen hepatotoxicity in man, however, inhibition of formation of the toxic metabolite does occur in both man and animals. When considered with the results of previous studies showing that cimetidine reduces the severity of acetaminophen-induced liver injury in animals (10) (11) (12) , the present study provides a rational basis for assessing possible benefit of cimetidine treatment of acetaminophen overdoses in man. One potential problem that might arise with the use of cimetidine for this purpose is in treatment of patients with multiple drug ingestions. In such a situation cimetidine may prolong the elimination of other drugs such as benzodiazepines and barbiturates (33) (34) . For these reasons, the use of cimetidine as a treatment of acetaminophen overdoses in man cannot be recommended at this time. Further studies to assess the usefulness of cimetidine as an adjunct to standard treatment of acetaminophen overdoses in man with N-acetylcysteine are warranted.
